Invesco Exchange-Traded Fund Trust II Invesco S&P Ultra Dividend Revenue ETF (ARCA: RDIV)

Últimas noticias sobre Invesco Exchange-Traded Fund Trust II Invesco S&P Ultra Dividend Revenue ETF (ARCA:RDIV)

Invesco Exchange-Traded Fund Trust II Invesco S&P Ultra Dividend Revenue ETF

Oppenheimer S&P Ultra Dividend Revenue ETF

Oppenheimer Ultra Dividend Revenue ETF

RevenueShares Ultra Dividend Fund

Financial Services

Utilities

Consumer Cyclical

Consumer Defensive

Basic Materials

Healthcare

Real Estate

Technology

Energy

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index includes positive revenue producing constituent securities of the S&P 900 Index (the parent index), which combines the S&P 500 Index and S&P MidCap 400 Index to form an investable benchmark for the large- and mid-cap universe of the U.S. equity market. The fund is non-diversified.

Pfizer, Inc.

Philip Morris International

Pnc Financial Services Group Inc.

Best Buy Co. Inc.

Prudential Financial Inc.

Us Bancorp

Duke Energy Corp Depositary Shs Repr 1/1000Th Cum Red Perp Pfund Registered Sh Series A

International Business Machines Corp.

Lyondellbasell Industries Nv

Ford Motor Credit

Invesco S&P Ultra Dividend Revenue ETF

Equities

News

Markets

Movers

Media

General

FTXR

RDIV

Ford (F) negocia una posible vuelta a la fabricación en India para exportación, mientras sus acciones caen un 0,97%.

¿Qué está pasando con las acciones de Ford Motor (F) este miércoles?

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

Price Target

Reiteration

Analyst Ratings

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) with a Buy and raises the price target from $24 to $26.

FBIO

HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26

B of A Securities analyst Tazeen Ahmad maintains PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) with a Neutral and lowers the price target from $10 to $6.

PEPG

B of A Securities Maintains Neutral on PepGen, Lowers Price Target to $6

WIIM

TUYA

Tuya shares are trading higher after the company announced an anchor investment by 65 Equity Partners.

Citigroup analyst Jonathan Woo initiates coverage on Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) with a Buy rating and announces Price Target of $65.

Initiation

AKRO

Citigroup Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $65

B of A Securities analyst Ruplu Bhattacharya initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $30.

INGM

B of A Securities Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $30

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) with a Buy and maintains $20 price target.

APRE

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

Citigroup analyst Atif Malik initiates coverage on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy rating and announces Price Target of $120.

ALAB

Citigroup Initiates Coverage On Astera Labs with Buy Rating, Announces Price Target of $120

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

BMO Capital analyst Jeffrey Silber upgrades Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from Market Perform to Outperform and lowers the price target from $137 to $125.

Upgrades

BFAM

BMO Capital Upgrades Bright Horizons Family to Outperform, Lowers Price Target to $125

Baird analyst Joe Vruwink maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and raises the price target from $305 to $330.

ADSK

Baird Maintains Outperform on Autodesk, Raises Price Target to $330

ARWR

Arrowhead Pharmaceuticals Submits New Drug Application To The US FDA For Plozasiran In Treatment Of Familial Chylomicronemia Syndrome

Loop Capital analyst Gary Mobley upgrades Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) from Hold to Buy and maintains the price target from $660 to $660.

MPWR

Loop Capital Upgrades Monolithic Power Systems to Buy, Maintains Price Target to $660

TWST

Twist Bioscience shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

CVS Health shares are trading higher after the company announced the addition of four new directors to its board.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and maintains $32 price target.

KURA

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

BIIB

Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.

MARA

Marathon Digital Holdings shares are trading lower after the company announced a $700 million convertible note offering to boost Bitcoin holdings and repurchase debt.

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.

QGEN

SYRS

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $154 to $162.

JAZZ

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162

Has The AI Trade Run Out Of Steam?

Momentum Investing Gives You An Edge, Until It Doesn't

Invesco Ultra Dividend Revenue ETF declares quarterly distribution of $0.5012

RDIV: Diverse ETF But Underperforms Peers

Q4 2024 Equity Market Outlook

RDIV: A High-Yield Dividend ETF, Modest Growth Driven By Its Sector Allocation

How Jobs Growth Informs The Backdrop For Multi-Asset Investing

Quarterly Trading Report - Q3 2024: The Big Rotation And The Big Cut

Think Value And Growth - Not Just Value Or Growth

Weekly Market Pulse: What Trump Bump?

ABEQ

ACTV

AFMC

AFSM

AIEQ

AIVL

ALTL

AMOM

ANEW

ARKF

ARKK

ARKQ

ARKW

ARKX

ARTY

ATFV

AUSF

AVEM

AVUV

BAPR

BBSC

BKSE

BLCN

BLOK

BMVP

BOTZ

BUFF

CALF

CBSE

CFCV

CIBR

CLOU

COWZ

DAPP

DBEM

DEEP

DEUS

DFAS

DFNV

DGRO

DGRS

DIVB

DIVO

DIVY

DIVZ

DTEC

DURA

DWAS

DWAW

DWUS

EDOW

EJUL

EQAL

EQRR

ESGE

ESML

ESPO

FBCG

FBCV

FCOM

FDIS

FDMO

FDRR

FDVV

FIBR

FINX

FITE

FLQM

FLQS

FMAG

FNDA

FNDB

FNDX

FNGS

FRDM

FSCS

FTDS

FTEC

FTXL

FUNL

FVAL

GAMR

GBIL

GBUY

GGRW

GINN

GLRY

GOVT

GOVZ

GRPM

GSSC

GURU

GVIP

HACK

Comments

Invesco Exchange-Traded Fund Trust II Invesco S&P Ultra Dividend Revenue ETF

Noticias

Últimas noticias sobre Invesco Exchange-Traded Fund Trust II Invesco S&P Ultra Dividend Revenue ETF (ARCA:RDIV)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL